DEVELOPMENT CANCER IMMUNOTHERAPY TREATMENT

Brand	Owner	Address	Description
ABSQUANT	immatics biotechnologies GmbH	Paul-Ehrlich-Strasse 15 Tübingen 72076 Germany	Development of cancer immunotherapy treatment options based on medical evaluation of individual patients;Research and development in the pharmaceutical and biotechnology fields; Medical research; Development of pharmaceutical preparations and medicines; Scientific research;
	Where the owner name is not linked, that owner no longer owns the brand

Technical Examples

A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of a natural cytokine mixture (NCM), an effective amount of cyclophosphamide (CY), or an effective amount of indomethacin (INDO), wherein the NCM, CY, or INDO are administered singly or in combinations thereof. An anti-metastatic treatment method by promoting differentiation and maturation of immature dendritic cells in a lymph node; allowing presentation thereof; and preventing development of metastasis. A method of using an NCM as a diagnostic skin test for predicting treatment outcome. A method of pre-treating dendritic cells (DC) and a method of treating monocyte defects characterized by sinus histiocytosis or a negative NCM skin test. Compositions and methods for eliciting an immune response to endogenous or exogenous tumor antigens.